PHERGAIN-2
OFFICIAL TITLE: CHEMOTHERAPY-FREE PCR-GUIDED STRATEGY WITH SUBCUTANEOUS TRASTUZUMAB-PERTUZUMAB AND T-DM1 IN HER2-POSITIVE EARLY BREAST CANCER (PHERGAIN-2)
PLANNED SITES
HER2+ EBC
II
393
70
Spain, Italy, Germany, Hungary, Bulgaria, Poland
Recruiting
PRESS RELEASE
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
SABCS 2021: - DOWNLOAD THE POSTER
TRIAL RESUME
PHERGAIN-2 SITES
SPAIN
Hospital General Universitario de Valencia
SPAIN
Hospital Universitari Dexeus
SPAIN
Hospital Arnau de Vilanova de Valencia
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Hospital Universitari Sant Joan de Reus
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Hospital Universitario de Basurto
SPAIN
Hospital General Universitario de Alicante
SPAIN
Hospital Provincial de Castellón
SPAIN
Instituto Valenciano de Oncología
SPAIN
Complejo Hospitalario de Jaén
SPAIN
Complejo Hospitalario Universitario A Coruña (CHUAC),
SPAIN
Hospital Universitario Reina Sofía
SPAIN
Hospital Clínico Universitario de Valencia
SPAIN
Institut Català d' Oncologia L'Hospitalet (ICO)
SPAIN
Hospital Clínico San Carlos
SPAIN
Hospital Universitario de León
SPAIN
Hospital Universitari Vall D'Hebrón
SPAIN
Hospital Quiron San Camilo- Ruber Juan Bravo
SPAIN
Hospital Universitario Clínico San Cecilio de Granada
SPAIN
Institut Català d'Oncologia Badalona (ICO)
SPAIN
Centro Oncológico de Galicia
SPAIN
Hospital Universitario de Torrejón
SPAIN
Hospital Arnau de Vilanova de Lleida
CLINICAL TRIAL DETAILS
THIS CLINICAL TRIAL EVALUATES THE EFFICACY OF A CHEMOTHERAPY-FREE PATHOLOGICAL COMPLETE RESPONSE (PCR)-GUIDED STRATEGY WITH TRASTUZUMAB AND PERTUZUMAB (GIVEN AS A SUBCUTANEOUS FIXED-DOSE COMBINATION) AND T-DM1, FOR PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE EARLY BREAST CANCER, BY ASSESSING THE 3-YEAR RECURRENCE FREE INTERVAL (3Y-RFI).
IN ADDITION, THE TRIAL WILL ASSESS THE GLOBAL HEALTH STATUS DECLINE RATE AT 1 YEAR FROM START OF NEOADJUVANT TREATMENT IN THIS TARGET POPULATION.
PHERGAIN-2 AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
COUNTRY
STATUS